Originator
Magnamycin,Pfizer,US,1953
Uses
Sixteen-membered-ring macrolite antibiotic complex similar to Leucomycin and Erythromycin, produced by Stroptomyces halstedii.
Definition
An antibiotic isolated from products of Strepto-
myces halstedii when grown in suitable media
by the deep-culture method. It inhibits growth of
certain gram-positive bacteria such as staphylo-
cocci, pneumococci, and hemolytic streptococci.
Manufacturing Process
A selected strain of Streptomyces halstedii was cultivated in an aqueous
nutrient medium under aerobic conditions and the resulting broth containing
carbomycin antibiotics was filtered. The solutions was extracted twice at pH
6.5 with one-quarter volume of methyl isobutyl ketone. The combined extracts
were concentrated to one-tenth volume under vacuum, and the antibiotics
were extracted into water adjusted to a pH of about 2 with sulfuric acid. After
adjusting the separated aqueous solution to pH 6.5, the antibiotic was
extracted into benzene and the solution was concentrated to a small volume.
Addition of hexane resulted in the separation of a solid product containing the
benzene complexes of carbomycin A and carbomycin B, present in the
fermentation broth.
brand name
Magnamycin
(Pfizer).
Therapeutic Function
Antibiotic
Safety Profile
Poison by
subcutaneous route. Moderately toxic by
intravenous and intramuscular routes. When
heated to decomposition it emits toxic
fumes of NOx.
